Related Articles
Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate
Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients
Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis